Literature DB >> 7513677

Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: a multivariate analysis of prognostic factors.

L Mondazzi1, R Bottelli, G Brambilla, A Rampoldi, I Rezakovic, C Zavaglia, A Alberti, G Idèo.   

Abstract

A total of 84 patients with hepatocellular carcinoma and cirrhosis were analyzed retrospectively to investigate prognostic factors. All patients received transarterial oily chemoembolization as the only anticancer therapy. The follow-up range was 1 to 39 mo (median, 9.5 mo). The overall actuarial survival rates at 12, 24 and 30 mo were 62%, 31% and 24%, respectively. According to univariate analysis, variables significantly associated with survival were age, Child-Pugh grade, total serum bilirubin, Okuda stage, tumor size, degree of labeling of the tumor with Lipiodol, gelatin foam use, changes with treatment in tumor size and changes with treatment in alpha-fetoprotein concentration. Two multivariate analyses were performed. When pretreatment and treatment variables were considered, parameters with independent prognostic value were age, Child-Pugh grade, total serum bilirubin, tumor size and degree of Lipiodol labeling of the tumor. When follow-up variables were also considered, we (a) confirmed the prognostic significance of all these parameters (age, Child-Pugh grade, total serum bilirubin, tumor size) and (b) found the independent prognostic value of the change in tumor size (or change in alpha-fetoprotein concentration). Both models yielded different risk coefficients for each class of each variable. Two simple prognostic indexes, based on these coefficients, are proposed: an "initial" index (including pretreatment and treatment variables) and a "follow-up" index (also including follow-up variables). According to the two indexes, the patients were classified into three groups with different prognoses: good (93% and 100% actuarial survival at 1 yr for the initial and follow-up indexes, respectively), intermediate (65% and 53%, respectively) and poor (27% for both indexes).

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7513677

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  46 in total

1.  Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre.

Authors:  A Grieco; M Pompili; G Caminiti; L Miele; M Covino; B Alfei; G L Rapaccini; G Gasbarrini
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

2.  Therapeutic results of computed-tomography-guided transcatheter arterial chemoembolization for local recurrence of hepatocellular carcinoma after initial transcatheter arterial chemoembolization: the results of 85 recurrent tumors in 35 patients.

Authors:  Mikio Tezuka; Keiji Hayashi; Yoichi Okada; Tetsuya Irie; Hiroyasu Ina
Journal:  Dig Dis Sci       Date:  2008-07-23       Impact factor: 3.199

Review 3.  Transcatheter embolization therapy in liver cancer: an update of clinical evidences.

Authors:  Yì-Xiáng J Wáng; Thierry De Baere; Jean-Marc Idée; Sébastien Ballet
Journal:  Chin J Cancer Res       Date:  2015-04       Impact factor: 5.087

4.  A high value of serum des-γ-carboxy prothrombin before hepatocellular carcinoma treatment can be associated with long-term liver dysfunction after treatment.

Authors:  Masaya Saito; Yasushi Seo; Yoshihiko Yano; Akira Miki; Masaru Yoshida; Takeshi Azuma
Journal:  J Gastroenterol       Date:  2012-03-24       Impact factor: 7.527

5.  Large-sized hepatocellular carcinoma (HCC): a neoadjuvant treatment protocol with repetitive transarterial chemoembolization (TACE) before percutaneous MR-guided laser-induced thermotherapy (LITT).

Authors:  Stephan Zangos; Katrin Eichler; Jörn O Balzer; Ralf Straub; Renate Hammerstingl; Christopher Herzog; Thomas Lehnert; Mathias Heller; Axel Thalhammer; Martin G Mack; Thomas J Vogl
Journal:  Eur Radiol       Date:  2006-08-08       Impact factor: 5.315

6.  Prognostic factors for survival in patients with unresectable hepatocellular carcinoma undergoing chemoembolization with doxorubicin drug-eluting beads: a preliminary study.

Authors:  Renumathy Dhanasekaran; David A Kooby; Charles A Staley; John S Kauh; Vinit Khanna; Hyun S Kim
Journal:  HPB (Oxford)       Date:  2010-04       Impact factor: 3.647

7.  Theranostics and contrast-agents for medical imaging: a pharmaceutical company viewpoint.

Authors:  Jean-Marc Idée; Stéphanie Louguet; Sébastien Ballet; Claire Corot
Journal:  Quant Imaging Med Surg       Date:  2013-12

8.  Chemoembolisation for hepatocellular carcinoma with bile duct invasion: is preprocedural biliary drainage mandatory?

Authors:  Juil Park; Hyo-Cheol Kim; Jeong-Hoon Lee; EunJu Cho; Minuk Kim; Saebeom Hur; Hwan Jun Jae; Myungsu Lee; Jin Wook Chung
Journal:  Eur Radiol       Date:  2017-11-09       Impact factor: 5.315

Review 9.  Hepatocellular carcinoma in the elderly: Meta-analysis and systematic literature review.

Authors:  Annie K Hung; Jennifer Guy
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

10.  Comparison of survival rates between patients treated with transcatheter arterial chemoembolization and hepatic resection for solitary hepatocellular carcinoma.

Authors:  Yasutaka Baba; Sadao Hayashi; Kazuto Ueno; Masayuki Nakajo; Shinichi Ueno; Fumitake Kubo; Yoshirou Baba; Masahiro Hamanoue; Susumu Hasegawa; Hirohito Tsubouchi; Yasuji Komorizono
Journal:  Oncol Lett       Date:  2010-09-01       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.